Is radioligand therapy ready for routine use in metastatic hormone-sensitive prostate cancer (mHSPC)?
In this EMUC TV interview, our UROONCO PCa associate editor Prof. Claudia Kesch speaks with Assoc. Prof. Matteo Bauckneht about the evolving evidence supporting PSMA-targeted radioligand therapy in earlier-stage metastatic disease.
Learn how recent clinical trials are shaping treatment strategies, the challenges of identifying the patients most likely to benefit, and why further research is needed to define the optimal place of radioligand therapy alongside established systemic treatments.